即刻两阶段乳房重建术中照射后扩张器与植入物交换的更佳时机

2022-02-28 MedSci原创 MedSci原创

乳腺癌术后放射治疗的适应证在基于植入物的乳房重建中适当放宽。据报道,乳腺癌术后放射治疗应该在组织扩张器放置后还是永久性植入物放置后完成仍存在争议性。

乳腺癌术后放射治疗的适应证在基于植入物的乳房重建中适当放宽。据报道,乳腺癌术后放射治疗应该在组织扩张器放置后还是永久性植入物放置后完成仍存在争议性。

但任何照射延迟都可能影响乳腺癌的局部区域控制和患者生存。因此,在实践中,许多患者在永久性植入前接受组织扩张器的放射治疗。

图1 文章来源

放射治疗增加了植入物相关并发症的风险,导致重建失败。术后即刻常见的问题是伤口愈合延迟和感染。其中囊膜挛缩发生在晚期,是植入物取出的主要原因。

该研究从短期和长期结果的角度研究了放疗后扩张器与植入物交换的最佳时机,并回顾性分析了2010年至2019年间连续接受两阶段乳房重建和放射治疗的患者。

根据受试者操作特征曲线和Youden指数,根据49天(早期)和2年(晚期)并发症,估算从放射治疗到植入的最佳时间。

结果显示,该研究共纳入133例。49天和2年的比较率分别为8.3%和29.7%。

囊膜粘连是最常见的2年并发症。

图2放射治疗后扩张器与植入物交换最佳时机的受试者操作特征分析,以预测最低的49天并发症。最大Youden指数显示,放疗结束后131天是进行扩张器-植入物交换的最佳时间点,对应于1和1的敏感性− 特异性为0.0573。曲线下的面积估计为0.7187(95%置信区间,0.5767至0.8607)。

Youden指数表明,放疗后131天植入物对减少49天并发症最有效,但2年并发症不太明显,敏感性和曲线下面积较低。

改良根治术、放疗时扩张器填充量和永久性植入物的大小增加了49天并发症的几率,但与2年并发症的几率无关。

为了减少短期并发症,植入种植体的最佳时间点是放疗后131天。然而,没有明显的时间间隔来减少长期并发症。包膜挛缩是放射损伤的一种不可逆并发症,不受照射后变量(包括照射时间或永久性植入物的大小)的影响。

原始文章:

Kim Ara,Bae Juyoung,Bang Sa-Ik et al. Optimal Timing of Expander-to-Implant Exchange after Irradiation in Immediate Two-Stage Breast Reconstruction.[J] .Plast Reconstr Surg, 2022, 149: 185e-194e.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1684891, encodeId=a4ec16848917b, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Thu May 05 09:21:34 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215950, encodeId=a5851215950a3, content=<a href='/topic/show?id=291a23643c2' target=_blank style='color:#2F92EE;'>#乳房重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23643, encryptionId=291a23643c2, topicName=乳房重建)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 09:46:51 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490948, encodeId=880f1490948f6, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520795, encodeId=aa461520e9552, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198241, encodeId=b1961198241e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da196447565, createdName=ms1000001337797820, createdTime=Tue Mar 01 05:46:26 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-05-05 lsj637
  2. [GetPortalCommentsPageByObjectIdResponse(id=1684891, encodeId=a4ec16848917b, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Thu May 05 09:21:34 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215950, encodeId=a5851215950a3, content=<a href='/topic/show?id=291a23643c2' target=_blank style='color:#2F92EE;'>#乳房重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23643, encryptionId=291a23643c2, topicName=乳房重建)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 09:46:51 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490948, encodeId=880f1490948f6, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520795, encodeId=aa461520e9552, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198241, encodeId=b1961198241e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da196447565, createdName=ms1000001337797820, createdTime=Tue Mar 01 05:46:26 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1684891, encodeId=a4ec16848917b, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Thu May 05 09:21:34 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215950, encodeId=a5851215950a3, content=<a href='/topic/show?id=291a23643c2' target=_blank style='color:#2F92EE;'>#乳房重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23643, encryptionId=291a23643c2, topicName=乳房重建)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 09:46:51 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490948, encodeId=880f1490948f6, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520795, encodeId=aa461520e9552, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198241, encodeId=b1961198241e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da196447565, createdName=ms1000001337797820, createdTime=Tue Mar 01 05:46:26 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1684891, encodeId=a4ec16848917b, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Thu May 05 09:21:34 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215950, encodeId=a5851215950a3, content=<a href='/topic/show?id=291a23643c2' target=_blank style='color:#2F92EE;'>#乳房重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23643, encryptionId=291a23643c2, topicName=乳房重建)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 09:46:51 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490948, encodeId=880f1490948f6, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520795, encodeId=aa461520e9552, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198241, encodeId=b1961198241e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da196447565, createdName=ms1000001337797820, createdTime=Tue Mar 01 05:46:26 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-03-01 jiyangfei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1684891, encodeId=a4ec16848917b, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Thu May 05 09:21:34 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1215950, encodeId=a5851215950a3, content=<a href='/topic/show?id=291a23643c2' target=_blank style='color:#2F92EE;'>#乳房重建#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23643, encryptionId=291a23643c2, topicName=乳房重建)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Sun May 01 09:46:51 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490948, encodeId=880f1490948f6, content=<a href='/topic/show?id=fb916268636' target=_blank style='color:#2F92EE;'>#植入物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62686, encryptionId=fb916268636, topicName=植入物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38628846382, createdName=linagood, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520795, encodeId=aa461520e9552, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Mar 01 12:21:34 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198241, encodeId=b1961198241e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da196447565, createdName=ms1000001337797820, createdTime=Tue Mar 01 05:46:26 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-03-01 ms1000001337797820

    学习了

    0

相关资讯

Molecular Cancer:基于工程化外泌体的原位树突状细胞肿瘤疫苗,用于乳腺癌治疗

作为最有效的抗原呈递细胞(APC),树突状细胞(DC)在肿瘤微环境中是启动和调节先天性和适应性免疫的核心,具有在肿瘤微环境中呈递肿瘤相关抗原(TAA)的能力。

European Radiology:加入了这一放射组学信息,乳腺良恶性病变的鉴别也许不再困难!

对比增强乳腺钼靶(CEM)是一种新兴的乳腺成像技术。它以双能量乳腺造影技术为基础,利用静脉注射碘化造影剂来描绘乳腺病变的增强情况。

European Radiology:对于确诊良性乳腺病变的患者来说,这些钼靶特征可与乳腺癌的风险增加相关

乳腺良性病变是乳腺癌筛查的中经常发现的非恶性乳腺病变。虽然乳腺钼靶检查的目的是进行早期乳腺癌筛查,但大多数病变的病理结果是良性乳腺病变(BBD)。

Lancet Oncol:芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌

接受卵巢抑制的绝经前女性使用芳香酶抑制剂相比他莫昔芬可进一步降低乳腺癌复发的风险

系统评价和荟萃分析:中医药联合化疗治疗乳腺癌

乳腺癌是我国女性常见的恶性肿瘤,其年发病率持续上升。每年大约有 280,000 例新发乳腺癌病例,乳腺癌是女性的头号杀手。近年来,紫杉类和蒽环类药物联合应用中药化疗,延长了乳腺癌患者的生存时间。

拓展阅读

JAMA Surg:自体脂肪移植vs植入物,哪种乳房重建更受乳腺癌患者青睐?

JAMA Surg:使用扩张装置进行自体脂肪转移或植入物的全乳房重建对乳腺癌患者生活质量的影响:一项随机临床试验

PRS:自体脂肪移植不同处理方法临床效果的前瞻性随机比较。

随着脂肪移植应用逐渐广泛,移植物处理也愈发受到临床重视。在移植过程中有三个关键步骤——收获、加工和移植,其中每个步骤都有几个可能影响移植效率和效果的变量。

PRS:脱细胞真皮基质有利地调节手术后的愈合反应

事实上,使用无细胞真皮基质可能会降低囊性挛缩率,并有利于分阶段进行胸前乳房重建的扩展。

PRS:乳房切除术前固定术在乳房重建中的作用

随着时间的推移,保留乳头的乳房切除术的适应症已扩大范围。但对于乳房肿大或下垂的患者,行保留乳头乳房切除术仍有发生皮瓣或乳头乳晕复合坏死的风险。因此需要一些干预来减小风险,保证手术效果。

乳房重建90 天时的临床和健康相关生活质量结果

在胸前放置组织扩张器进行两期植入性乳房重建可潜在地减少胸壁发病率和术后疼痛。

乳房再造手术决策中的认知偏差和治疗选择

了解医学专家及其患者如何处理和传递信息对于高效的医疗保健专业愿景至关重要。

乳腺癌患者乳房重建决策指导的最佳证据总结

浙江中医药大学护理学院 · 2024-04-05

乳腺肿瘤整形与乳房重建专家共识(2022年版)

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2022-09-30

乳腺癌术后乳房重建中国专家共识(2019版)

中华医学会外科学分会 乳腺外科学组 · 2019-11-30

2014 ASPS临床实践指南:应用扩展器和植入物进行乳房重建

美国整形外科医师学会(ASPS,American Society of Plastic Surgeons) · 2014-10-20